China Kadoorie Biobank of 0.5 million adults (360G-Wellcome-212946_Z_18_Z)

CKB is a blood-based prospective cohort study of 512,000 adults, recruited from 10 diverse areas across China (during 2004-08), with extensive data collection at baseline and subsequent resurveys and long-term storage of biological samples. By 1.1.2017, ~43,000 deaths and ~0.9M coded episodes of hospitalisation had been recorded. These exposure and outcome data are complemented by separately funded genotyping (currently for 102,000 participants), whole genome sequencing, and conventional and multi-omics assays for nested case-control studies of specific diseases. This proposal seeks support for 5 years to maintain, enhance and share the resource through: (i) continued follow-up for fatal and non-fatal disease events by linkage to mortality/morbidity registries and health insurance systems; (ii) ascertainment, adjudication and sub-phenotyping of major disease outcomes (e.g. stroke, IHD, cancer); (iii) resurvey of ~25,000 survivors with additional enhancements (e.g. accelerometers) and sample collection (e.g. faecal/saliva samples); (iv) maintenance, enhancement and development of IT systems underpinning the infrastructure and co-ordination of the study; (v) processing, managing and sharing large and complex data with the wider research community; (vi) secure bio-repositories with DNA extraction and sample reformatting. CKB is a global resource with huge potential to improve our understanding of disease aetiology, risk prediction and development of new therapies.